Literature DB >> 32306499

Integration of miRNA-regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease.

Fida Azar1, Kevin Courtet1,2, Bassil Dekky1, Dominique Bonnier1, Olivier Dameron2, Alain Colige3, Vincent Legagneux1, Nathalie Théret1,2.   

Abstract

BACKGROUND & AIMS: Activation of hepatic stellate cells (HSC) is a critical process involved in liver fibrosis. Several miRNAs are implicated in gene regulation during this process but their exact and respective contribution is still incompletely understood. Here we propose an integrative approach of miRNA-regulatory networks to predict new targets.
METHODS: miRNA regulatory networks in activated HSCs were built using lists of validated miRNAs and the CyTargetLinker tool. The resulting graphs were filtered according to public transcriptomic data and the reduced graphs were analysed through GO annotation. A miRNA network regulating the expression of TIMP3 was further studied in human liver samples, isolated hepatic cells and mouse model of liver fibrosis.
RESULTS: Within the up-regulated miRNAs, we identified a subnetwork of five miRNAs (miR-21-5p, miR-222-3p, miR-221-3p miR-181b-5p and miR-17-5p) that target TIMP3. We demonstrated that TIMP3 expression is inversely associated with inflammatory activity and IL1-ß expression in vivo. We further showed that IL1-ß inhibits TIMP3 expression in HSC-derived LX-2 cells. Using data from The Cancer Genome Atlas (TCGA), we showed that, in hepatocellular carcinoma (HCC), TIMP3 expression is associated with survival (P < .001), while miR-221 (P < .05), miR-222 (P < .01) and miR-181b (P < .01) are markers for a poor prognosis.
CONCLUSIONS: Several miRNAs targeting TIMP3 are up-regulated in activated HSCs and down-regulation of TIMP3 expression is associated with inflammatory activity in liver fibrosis and poor prognosis in HCC. The regulatory network including specific miRNAs and TIMP3 is therefore central for the evolution of chronic liver disease.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  TIMP3; hepatic stellate cells; liver fibrosis; miRNA networks

Mesh:

Substances:

Year:  2020        PMID: 32306499     DOI: 10.1111/liv.14476

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types.

Authors:  Guoshu Bi; Jiaqi Liang; Yuansheng Zheng; Runmei Li; Mengnan Zhao; Yiwei Huang; Cheng Zhan; Songtao Xu; Hong Fan
Journal:  J Transl Med       Date:  2021-03-25       Impact factor: 5.531

2.  The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.

Authors:  Dominika Kazmierczak; Karol Jopek; Karolina Sterzynska; Michal Nowicki; Marcin Rucinski; Radoslaw Januchowski
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

3.  Pep19 Has a Positive Effect on Insulin Sensitivity and Ameliorates Both Hepatic and Adipose Tissue Phenotype of Diet-Induced Obese Mice.

Authors:  Renata Silvério; Robson Barth; Andrea S Heimann; Patrícia Reckziegel; Gustavo J Dos Santos; Silvana Y Romero-Zerbo; Francisco J Bermúdez-Silva; Alex Rafacho; Emer S Ferro
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

4.  Macrophage nuclear factor erythroid 2-related factor 2 deficiency promotes innate immune activation by tissue inhibitor of metalloproteinase 3-mediated RhoA/ROCK pathway in the ischemic liver.

Authors:  Jianhua Rao; Jiannan Qiu; Ming Ni; Hao Wang; Peng Wang; Lei Zhang; Zeng Wang; Mu Liu; Feng Cheng; Xuehao Wang; Ling Lu
Journal:  Hepatology       Date:  2021-12-10       Impact factor: 17.298

Review 5.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.